New combo shrinks prostate tumors before radiation in early trial
NCT ID NCT02160353
First seen Apr 14, 2026 · Last updated May 15, 2026 · Updated 4 times
Summary
This study tested whether giving a combination of abiraterone acetate, prednisolone, and a hormone-blocking drug for about 4 months before radiation could shrink tumors and lower PSA in 45 men with high-risk localized prostate cancer. The goal was to improve treatment response before starting radiation. Results showed reductions in tumor size, PSA, and prostate volume, but long-term disease control still requires ongoing management.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH RISK LOCALISED PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cork University Hospital
Cork, Ireland
-
St Luke's Hospital
Dublin, 6, Ireland
-
University Hospital Galway
Galway, Ireland
Conditions
Explore the condition pages connected to this study.